Warning letter
Custom Compounding Centers, LLC: warning letter of May 15, 2013
FDA warning letter 391363 · Los Angeles District Office
Key facts
| Reference number | 391363 |
|---|---|
| Company | Custom Compounding Centers, LLC |
| Subject | Unapproved and Misbranded New Drugs |
| Issue date | May 15, 2013 |
| Posted date | May 15, 2013 |
| Issuing office | Los Angeles District Office |
| Product type | Drugs |
| CFR sections cited | 201.115, 211, 211.192, 211.42(c)(10)(iii), 211.42(c)(10)(iv), 211.113(b), 211.166(a) |
| Inspection city | Los Alamitos |
| Inspection ZIP | 90720 |
| Inspection start date | Nov 14, 2012 |
| Letter on fda.gov | web.archive.org |
At a glance
- 1–9 CFR sections cited
- OAI Linked inspection classification
- Yes Form FDA 483 issued
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA warning letters
FDA warning letters notify a firm of significant regulatory violations found during an inspection or review and request prompt corrective action.
Source: U.S. Food and Drug Administration (FDA), Warning Letters · Source date: